United StatesA federal judge in Colorado has blocked the state's Prescription Drug Affordability Board from implementing a price cap on a major drug produced by Amgen. The decision, issued on July 2, 2026, ruled that Amgen is 'likely to be significantly harmed' by the proposed cap, effectively halting the initiative. The board, established four years ago to address rising prescription drug costs, had already begun setting upper payment limits on certain medications. While several states have similar affordability boards, Colorado has been particularly proactive in identifying costly drugs and imposing price controls. The ruling highlights ongoing tensions between state efforts to regulate drug prices and the pharmaceutical industry's pushback against such measures.
Bias read (Right): The article frames the judge's decision as a victory for the pharmaceutical industry, emphasizing potential harm to Amgen rather than focusing on patient affordability or public health concerns. The language suggests support for corporate interests over regulatory action aimed at lowering drug costs
